Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIG001 in Advanced Solid Tumors
NCT07486700Phase 1Not yet recruiting
- Sponsor
- Peking University
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Biologic, TE (Tissue engineering), RM (Regenerative Medicine)
- Countries
- 1
01
Overview
Phase 1, open-label trial of Signature Cord Prime in solid tumor (advanced stage) (2 arms), sponsored by Peking University. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Plasma Concentration at 28 days and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Signature Cord Prime
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07486700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486700.